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Abstract

Published: September 6, 2017

Glioblastoma is the most common and lethal malignant primary brain tumor for which the
development of efficacious chemotherapeutic agents remains an urgent need. The anti-helminthic drug niclosamide, which has long been in use to treat tapeworm infections, has
recently attracted renewed interest due to its apparent anticancer effects in a variety of in
vitro and in vivo cancer models. However, the mechanism(s) of action remains to be elucidated. In the present study, we found that niclosamide induced cell toxicity in human glioblastoma cells corresponding with increased protein ubiquitination, ER stress and
autophagy. In addition, niclosamide treatment led to down-regulation of Wnt/β-catenin,
PI3K/AKT, MAPK/ERK, and STAT3 pro-survival signal transduction pathways to further
reduce U-87 MG cell viability. Taken together, these results provide new insights into the
glioblastoma suppressive capabilities of niclosamide, showing that niclosamide can target
multiple major cell signaling pathways simultaneously to effectively promote cell death in U87 MG cells. Niclosamide constitutes a new prospect for a therapeutic treatment against
human glioblastoma.
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Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
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Glioblastoma multiforme is the most common and aggressive brain tumor (World Health
Organization grade IV) for which an effective pharmacotherapy remains unavailable. The current initial treatment combines surgery with chemotherapy, yet the overall survival rate for glioma has not significantly improved in the past three decades because these tumors have a high
incidence of recurrence and commonly lead to death within less than a year from diagnosis
[1–3]. Extensive research has been done to identify more effectual antitumor regiments. Many
efforts have been made to screen small molecular inhibitors against gliomas, however, firstgeneration inhibitors that selectively disrupt single targets or block a specific signaling pathway

PLOS ONE | https://doi.org/10.1371/journal.pone.0184324 September 6, 2017

1 / 18

Cell toxicity and anticancer properties of niclosamide in glioblastoma

have failed to demonstrate clinical benefit in most patients with gliomas due to chemoresistance against antitumor treatments [4–6]. The mechanisms that lead to chemoresistance,
which account for the limited efficacy of current glioma therapies, are not fully understood.
Therefore, the development of new, more effective approaches that act through basic molecular mechanisms is critical to improve the prognosis for this type of tumor. One strategy to
improve anti-cancer treatment and/or circumvent chemoresistance is to simultaneously disrupt multiple known oncogenic signaling pathways using either multiple single-target or
multi-target therapeutics. It has been reported that up-regulation of the PI3K/AKT and
MAPK/ERK pathways is involved in glioma tumorigenesis and aberrant tumor growth [7]. In
addition, the well-known oncogene STAT3, a member of the STAT (signal transducers and
activators of transcription) family that is de-regulated in a variety of cancers, is also important
in glioblastoma tumorigenesis, as evidenced by the facts that STAT3 is activated in a high percentage of glioblastomas and its activation is associated with tumor grade and poor prognosis
[8–10]. It has been suggested that controlling pro-survival signaling pathways as well as other
molecular targets like STAT3 may represent a novel and effective therapeutic strategy for the
treatment of gliomas [11]. Identification of a single multi-target agent that is already safely
used by patients would be ideal seeing as it could be quite potent against aggressive tumors
and it could be more quickly implemented in cancer treatment.
Niclosamide, an FDA approved oral anti-helminthic drug, has been used for nearly 50
years to treat most tapeworm infections due to its efficacy in inhibiting mitochondrial oxidative phosphorylation and anaerobic adenosine triphosphate (ATP) production [12]. Studies
in the past few years have demonstrated that niclosamide is a promising chemotherapeutic
agent. A number of research groups have reported that niclosamide had potent anti-proliferative activity and induced cytotoxicity in a broad spectrum of cancer cells including solid
tumor cells, e.g. head and neck cancer [13]; non-small cell lung cancer [14]; prostate cancer
[15]; colon cancer [16]; ovarian cancer [17–18]; acute myelogenous leukemia (AML) [19];
osteosarcoma [20]; and breast cancer [21–22]. It has been shown that niclosamide effectively
limits different types of cancer growth both in vitro and in vivo by triggering apoptosis and
oxidative stress or by inhibiting several important signaling pathways including Wnt/β-catenin [23–25], mTOR [26], NFκB [19], and STAT3 [14,27]. Intriguingly, it was also discovered
that niclosamide stimulates autophagy, an intracellular process by which unessential or ineffectual cytoplasmic components are degraded [26]. Recently, a study of primary human glioblastoma cells identified niclosamide as a potential anticancer agent against glioblastoma
given that it demonstrated cytotoxic and anti-migratory effects [28]. However, studies
exploring putative anticancer properties in glioma cells are limited, and the molecular mechanisms underlying its effects remain poorly understood. Therefore, the present study aims to
describe anti-glioblastoma properties of niclosamide in the human U-87 malignant glioma
(MG) cell line.
In this study, we observed that niclosamide inhibits U-87 MG cell proliferation and it
induces accumulation of ubiquitinated proteins, apoptosis, ER stress, autophagy, and cell
death. Furthermore, we found that niclosamide not only inhibits STAT3 and Wnt/β-catenin
signaling, which has been seen in other cancer cells, but it also down-regulates two other prosurvival signal pathways (PI3K/AKT and MAPK/ERK) in these cells. These findings show that
niclosamide is a putative candidate for use in brain cancer treatment and understanding the
mechanism of action of niclosamide will facilitate the development of more effective
chemotherapeutics.
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Materials and methods
Reagents
Niclosamide and autofluorescent agent Monodansylcadaverine (MDC) were purchased from
Sigma-Aldrich (St. Louis, MO). Niclosamide was dissolved in DMSO at a 10 mM concentration and stored at –20˚C.

Cell culture
The human glioblastoma U-87 MG cell line was purchased from the American Type Culture
Collection (ATCC HTB-14, Manassas, VA). Cells were cultured at 5% CO2 at 37˚C in DMEM
supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin
(100 μg/mL). Cells were sub-cultured weekly onto 60 mm or 100 mm tissue culture dishes and
used for experiments at 85–90% confluence. The cell culture medium was replaced every 2–3
days.

Cell viability assays
MTS assay [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-thoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium, inner salt] was performed in 96-well plates using a CellTiter 96 non-radioactive cell proliferation colorimetric assay kit (Promega, Madison, WI) according to manufacturers’ instructions. Briefly, cells (8,000 cells in 200 μl medium per well) were plated in 96-well
plates the day before the experiment. At the end of various treatments, 100 μl medium was
removed from well, followed by the addition of 20 μl of MTS solution to each well and then
incubated for 1 h at 37˚C. Samples were read by a microplate reader at a wavelength of 490
nm. At least 6 replicates of each treatment were used.

Monodansylcadaverine (MDC) staining
The autofluorescent agent MDC (Sigma-Aldrich) was used as a specific autophagolysosome
marker to analyze the autophagic process [29]. U-87 MG cells were seeded on glass-bottom
slides in growth medium and incubated overnight. Cells were treated with or without 5 μM
niclosamide for 24 h. The cells were incubated with 0.05 mM MDC for another 1 h at 37˚C,
and then washed four times with PBS (pH 7.4). Cells were immediately visualized and imaged
by confocal microscopy.

Western blot analysis
Changes in the amounts of protein expression were measured by Western blot analysis. Protein homogenates were prepared as follows: the cells were lysed in ice-cold RIPA lysis buffer
containing protease and phosphatase inhibitor cocktails (Santa Cruz Biotechnology, Santa
Cruz, CA). Clear lysates were obtained by centrifugation at 4˚C for 20 min at 13,000 rpm in a
refrigerated microcentrifuge. Protein concentrations were determined, according to the manufacturer’s instruction, using the Pierce BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
Equal amounts of the protein samples (25–30 μg) were separated on a 10% or 4–20% gradient
polyacrylamide gel (Bio-Rad Laboratories, Hercules, CA), transferred to nitrocellulose membranes, and blocked for either 1 h at room temperature or overnight at 4˚C with Tris buffer
containing 0.1% Tween 20 (TBS-T, pH 7.4) and 5% (w/v) nonfat dried milk. The blotted membranes were incubated with specific primary antibodies for 1 h at room temperature or overnight at 4˚C. Ubiquitin, cyclin D1, survivin, P-ERK and ERK antibodies were purchased from
Santa Cruz Biotechnology while P-AKT, AKT, CHOP, LC3, Cleaved PARP, and cleaved caspase-3 antibodies were purchased from Cell Signaling (Beverly, MA). β-Actin loading control
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was obtained from Sigma-Aldrich. The membranes were washed and incubated for 1 h with
appropriate horseradish peroxidase-conjugated secondary antibodies. The protein bands were
detected using a chemiluminescent (ECL) method, according to the manufacturer’s instructions. Band densities were analyzed by ImageJ software.

Statistical analysis
Statistical analysis was undertaken using one-way analysis of variance and Tukey comparison
test, using GraphPad Prism 4.0 (GraphPad Software). Data is presented as the mean ± SEM of
at least three independent experiments. In the figures, asterisks indicate the degree of significance difference ( p0.05,  p0.001) between different treated cell cultures in comparison
to untreated controls.

Results
Niclosamide promotes apoptosis by protein ubiquitination
Dysregulation of apoptosis, or programmed cell death, is a hallmark of cancer as it is a critical
cellular process by which damaged or abnormal cells are eliminated. Niclosamide has been
shown to promote apoptosis in various cancer cells including U-87 MG cells [28]. To confirm
this effect against U-87 MG cells, cells were treated with increasing concentrations of niclosamide (0–40μM) for 24 hours. MTS assay was used to measure cell proliferation and viability as
described in the Material and Methods. As shown in Fig 1, niclosamide significantly inhibits
cell proliferation/viability in a dose-dependent manner.
The ubiquitin-proteasome system (UPS) is another important cellular signal transduction
pathway necessary for the degradation of intracellular proteins and it can play a role in the regulation of pathways necessary for tumor cell growth and survival. Studies have shown that ubiquitination also can play a role in the regulation of apoptosis [30–31]. A previous study has
shown that niclosamide was able to prevent the formation of large ubiquitin-containing aggregates caused by proteasome inhibition in human neuroblastoma SH-SY5Y cells by selectively
targeting proteins for degradation via the lysosomes or another proteasome-independent pathway [32]. Therefore, we investigated whether or not exposure to niclosamide could also suppress protein ubiquitination in U-87 MG cells. Ubiquitinated proteins were detected by
Western blot analyses with ubiquitin antibody (Fig 2). Remarkably, treatment with niclosamide resulted in an increase in the level of ubiquitinated proteins, suggesting niclosamide can
trigger the accumulation of ubiquitin-containing aggregates in U-87 MG cells. As shown in
Fig 2A, an increase in protein ubiquitination could be observed within 30 minutes of exposure
to niclosamide in comparison to untreated control and remained elevated thereafter. Detection of ubiquitinated proteins appeared to decrease slightly after 16 hours, possibly due to partial protein degradation by the UPS. To assess whether or not the increase of abundant protein
ubiquitination following treatment with niclosamide is specific to U-87 MG cells, an additional
human glioblastoma cell line (U-118 MG), one fibroblast cell line, one osteosarcoma cell line
and two breast cancer cell lines were treated with different concentrations of niclosamide for
24 h. Western blot analysis of U-118 MG cells showed similar results to U-87 MG cells (S1
Fig). Exposure to niclosamide resulted in a substantial increase of protein ubiquitination. In
contrast, western blot analysis showed no obvious change in ubiquitinated protein levels
between treated and untreated controls in the other tested cell lines (S2 Fig). The effect of
niclosamide on protein ubiquitination has not previously been reported for any human glioblastoma cell line and the data suggests that the effect may be unique to human glioblastoma
cells. We also examined whether or not the increase of ubiquitinated proteins following niclosamide treatment is caused by proteasome inhibition. Niclosamide had no significant effect on
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Fig 1. Niclosamide treatment reduces U-87 MG cell viability. U-87 MG cells were treated with the
indicated concentrations of niclosamide for 24 h. Cell viability was determined by MTS assay. Data represent
the mean ± S.E.M of at least three independent experiments. (***) p<0.001.
https://doi.org/10.1371/journal.pone.0184324.g001

proteasome activity in U-87 MG cells (S2 Fig) as measured by a 20S proteasome activity assay
[33].
Finally, cells were treated with 2.5 μM or 5 μM niclosamide for 24 hours and Western blot
analysis was performed with ubiquitin antibody and PARP (Poly ADP ribose polymerase)
antibody, a well-known and commonly used marker for apoptosis. As shown in Fig 2B and
2C, treatment with niclosamide resulted in a significant increase in expression of ubiquitinated
proteins. Cleaved PARP expression also significantly increased in U-87 MG cells following
exposure to niclosamide (Fig 2B and 2D), which is consistent with previous results in primary
human glioblastoma cells [28] and with our results demonstrating that niclosamide inhibits
cell viability. Given that reduced cell viability and increased PARP expression were concomitant with an increased level of ubiquitinated proteins, these results suggest that niclosamide
may have induced apoptosis in U-87 MG cells by promoting protein ubiquitination.

Niclosamide induces ER stress and activates autophagy
It has been demonstrated that accumulation of misfolded or ubiquitinated proteins can function like proteasome inhibition and induce endoplasmic reticulum (ER) stress [34–36]. ER
stress is a cellular response to the disruption of ER function. Failure to eliminate aberrant proteins and regain ER homeostasis can lead to severe cellular stress which then triggers cell
death. This event is mediated by specific pathways involving proteins such as CHOP/
GADD153 (C/EBP homology protein or growth arrest and DNA damage inducible protein
153) [35,37]. ER stress is associated with a variety of human disease including cancer. To determine whether or not niclosamide treatment can stimulate ER stress, U-87 MG cells were
treated with 5 μM niclosamide for various time periods up to 24 hours. Cells were then collected and cell lysates were utilized for Western blot analysis with CHOP antibody given that
CHOP is a major ER stress-associated protein. As expected, niclosamide promoted accumulation of CHOP in a time-dependent manner (Fig 3A).
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Fig 2. Niclosamide promotes protein ubiquitination and apoptosis in U-87 MG cells. (A) U-87 MG cells were treated with 5 μM
niclosamide and cells were collected at the indicated time points. Total cell lysates were resolved by SDS-PAGE and immunoblotted with
antibody specific to ubiquitin. (B) Total cell lysates were isolated from U-87 MG cells treated with the indicated concentrations of niclosamide
for 24 h, resolved by SDS-PAGE and then immunoblotted with antibody specific for ubiquitin and PARP, an apoptotic protein. β-Actin was
utilized as a loading control. The image is representative of at least three independent experiments. Relative expression levels of
ubiquitinated proteins and cleaved PARP protein from cells with and without niclosamide treatment were quantified by densitometry (C and
D, respectively). Data represent the mean ± S.E.M of at least three independent experiments. (***) p<0.01 and (*) p<0.05, respectively;
NS = no significant difference.
https://doi.org/10.1371/journal.pone.0184324.g002

Recent studies have found that ER stress is linked to autophagy which can function as a protective mechanism during ER stress [35,38]. As niclosamide has also been reported to induce
autophagy in human breast cancer MCF-7 cells [26], we next aimed to investigate whether
niclosamide has any influence on autophagy in U-87 MG cells. First, cells were treated with
5 μM niclosamide and cell lysates were collected at different time points up to 24 hours. Western blot analysis was carried out using LC3 (light chain 3) antibody, a widely-used marker for
autophagy. The conversion of cytosolic LC3-I to membrane-bound LC3-II indicates autophagic activity, specifically the formation of autophagosomes. As shown in Fig 3A, niclosamide
caused a time-dependent increase in LC3-II protein levels in U-87 MG cells, indicating activation of autophagy. Next, cells were treated with different concentrations of niclosamide for 24
hours. Treatment with either 2.5 μM or 5 μM niclosamide resulted in expression of LC3-II and
the autophagy response (Fig 3B). To further confirm that niclosamide induces autophagy,
monodansylcadaverine (MDC), a fluorescent compound, was used to stain niclosamidetreated cells. As shown in the Fig 3C, abundant autophagic vacuoles appeared in the cytoplasm
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Fig 3. Niclosamide triggers ER stress and the autophagic response in U-87 MG cells. (A) U-87 MG cells
were treated with 5 μM niclosamide and collected at the indicated time points. Total cell lysates were resolved
on SDS-PAGE and immunoblotted with antibodies specific for CHOP and LC3. (B) U-87 MG cells were
treated with 2.5 or 5 μM niclosamide and total protein was isolated from lysed cells after 24 h. Lysates were
resolved on SDS-PAGE and immunoblotted with LC3-specific antibody. (C) Representative image of U-87
MG cells incubated with 5 μM niclosamide for 24 h and then stained with MDC (0.05 mM). Fluorescence
particles in the cytoplasm indicate autophagic vacuoles.
https://doi.org/10.1371/journal.pone.0184324.g003

of cells exposed to 5 μM niclosamide for 24 hours, whereas a lesser amount of fluorescent dots
could be observed in the cytoplasm of control (untreated) cells.

Niclosamide inhibits Wnt/β-catenin signaling which can facilitate
apoptosis
The Wnt/β-catenin signaling pathway is involved in cell proliferation, differentiation, and
migration and it is required for neural stem cell development. Many studies have demonstrated that Wnt/β-catenin signaling is up-regulated in glioblastoma and can promote glioblastoma growth and invasion given its function in stem cell development [39]. Therefore, we
wanted to analyze the effect of niclosamide on Wnt/β-catenin signaling in U-87 MG cells by
Western blot analysis. Cells were treated with two levels of niclosamide (2.5 μM or 5 μM). As
shown in Fig 4A, β-catenin expression levels were markedly decreased after exposure to
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Fig 4. Niclosamide represses expression of β-catenin and its downstream effectors. (A) U-87 MG cells were treated with two levels of
niclosamide as indicated in the figure for 24 h. Total protein isolated from cell lysates were resolved by SDS-PAGE and immunoblotted with
antibodies specific for β-catenin and proteins from two target genes, cyclin D1 and survivin. β-Actin was used as a loading control. (B) Time
course effect of niclosamide on the expression of cyclin D1 and survivin.
https://doi.org/10.1371/journal.pone.0184324.g004

niclosamide for 24 hours, suggesting that niclosamide has an inhibitory effect on Wnt/β-catenin signaling. We then examined the expression of two β-catenin downstream targets, survivin
and cyclin D1, in U-87 MG cells. Cyclin D1 is a critical protein required for cell cycle progression whereas survivin negatively regulates apoptosis by inhibiting caspase activation. Similar
to β-catenin, both cyclin D1 and survivin expression were significantly suppressed after
24-hour treatment with niclosamide (Fig 4A). Furthermore, their expression levels decreased
in a time-dependent manner (Fig 4B). These results suggest that niclosamide inhibits cell cycle
progression, reduces cell viability, and facilitates apoptosis in U-87 MG cells by inhibiting
Wnt/β-catenin signaling.
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Niclosamide inhibits PI3K/AKT and MAPK/ERK pro-survival signal
transduction
The PI3K/AKT pathway is an intracellular signaling cascade important in regulating the cell
cycle and it is directly related to cellular proliferation and cancer development. The MAPK/
ERK signaling pathway is an evolutionarily conserved kinase module that links extracellular
signals to cellular responses that control fundamental cellular processes such as proliferation,
differentiation, and apoptosis. Given the importance of these two signal transduction pathways, they can often interconnect [40]. Previous studies have shown that niclosamide does not
impair PI3K/AKT signaling and has little effect on the MAPK/ERK signaling pathway in
MCF-7 cells [41]. However, we wished to evaluate whether or not niclosamide may have an
effect on these signaling pathways in U-87 MG cells, Western blot analysis was conducted
using phosphorylated/activated AKT, total AKT, phosphorylated/activated ERK, and total
ERK antibodies (Fig 5). Surprisingly, niclosamide treatment resulted in a reduction of both
phosphorylated AKT and total AKT over time which corresponds with the decrease in cell viability that we had observed after 24 h treatment. Niclosamide treatment also appeared to suppress both ERK phosphorylation and ERK expression in a time-dependent manner. The data
suggests that niclosamide has an inhibitory effect on upstream regulators of AKT and ERK
which subsequently affects their expression and activation and leads to disruption of AKT and
ERK function on their downstream effectors.

Niclosamide suppresses STAT3 to inhibit cell survival
STAT3 regulates major cellular processes such as cell growth, survival and differentiation and,
as previously mentioned, it is dysregulated in a number of cancers and thereby is intimately
linked to tumorigenesis. Studies have demonstrated that niclosamide is a potential anticancer
drug against cancers with activated STAT3 given that it can disrupt STAT3 transcription
[14,27]. Also, evidence has shown that inhibition of STAT3 with niclosamide in lung cancer
cells resulted in increased sensitivity to radiotherapy [42]. To determine whether or not niclosamide has any effect on the STAT3 signaling pathway in U-87 MG cells, we used immunoblotting for phosphorylated/activated STAT3 and total STAT3. Cells were treated with 5 μM
niclosamide for different time periods up to 24 hours. As shown in Fig 6, niclosamide-treated
cells showed a decrease in expression of both STAT3 and phosphorylated STAT3 in a timedependent manner like ERK. Hence, niclosamide may inhibit cell proliferation of U-87 MG
cells, in part, by mediating inhibition of STAT3 expression and activation.

Discussion
Recent studies have shown that niclosamide is cytotoxic and, more importantly, it exhibits
anticancer activity in different cancer cell lines. It has been demonstrated that, like many other
anticancer reagents, niclosamide has an effect on various important cellular mechanisms
involved in carcinogenesis. Niclosamide is able to inhibit signaling pathways such as Wnt/βcatenin, NF-κB (a regulator of inflammation), STAT3, and mTORC1 (a negative regulator of
autophagy), depending on cancer cell type. However, the effect of niclosamide on human glioblastoma has not been thoroughly studied. Our study aimed to investigate the effect of niclosamide in the human glioma U-87 MG cell line. In the current study, we sought to evaluate the
toxicity of niclosamide in U-87 MG cells. Our results are consistent with other published
reports on the mechanisms of niclosamide-induced apoptotic cell death in other model systems, suggesting that niclosamide may employ common cytotoxic signaling pathways in different cancer cell lines. Results presented in this study demonstrated that niclosamide
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Fig 5. Niclosamide suppresses AKT and ERK expression in U-87 MG cells. U-87 MG cells were treated
with 5 μM niclosamide and cells were collected at time points indicated in the figure. Total protein was isolated
from treated cells, resolved by SDS-PAGE and immunoblotted with specific antibodies against P-AKT, AKT,
P-ERK and ERK. β-Actin was used as a loading control.
https://doi.org/10.1371/journal.pone.0184324.g005

dramatically inhibits U-87 MG cell growth and proliferation, which correlates with results
from a previous study [25]. Significant anti-proliferative actions could be detected at tested
concentrations from 0.625–40 μM (Fig 1) in a dose-dependent manner.
Previous studies have shown controversial results regarding the effect of niclosamide on
protein ubiquitination. It was reported that niclosamide was able to prevent the formation of
large ubiquitin-containing aggregates in human neuronal SH-SY5Y cells [32]. However, this
finding is contrary to some recent reports showing that niclosamide increases formation of
Tax-ubiquitinated aggregates and protein ubiquitination of β-catenin [19,43]. Hence, we
attempted to test any effect of niclosamide on protein ubiquitination in U-87 MG and U-118
MG cells. Surprisingly, exposure of U-87 MG cells or U-118 MG cells to niclosamide tremendously induced protein ubiquitination (Fig 2 and S1 Fig, respectively) without significant

Fig 6. Niclosamide inhibits STAT3 expression. Total protein was isolated from U-87 MG cells treated with 5 μM
niclosamide at the times indicated in the figure. Lysates were resolved by SDS-PAGE and immunoblotted with either
P-STAT3 or STAT3-specific antibodies. β-Actin was used as loading control.
https://doi.org/10.1371/journal.pone.0184324.g006
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change to proteasome activity (S3 Fig). For the first time, we demonstrate that niclosamide is
capable of producing pronounced protein ubiquitination in human glioma U-87 MG and U118 MG cells at a level similar to that induced by proteasome inhibitors, agents that have been
extensively studied for their potential potent anticancer properties. This result implies that the
accumulation of ubiquitin-containing protein aggregates in glioblastoma cells may suppress
cell proliferation and trigger apoptosis. Indeed, our Western blot analysis shows that niclosamide induces apoptosis in U-87 MG cells (Fig 2B). Xiang et al. reported that niclosamide
down-regulated the retroviral oncoprotein Tax in HTLV-1-transformed T cell by promoting
the formation of polyubiquitinated Tax protein aggregate, facilitating its subsequent degradation in the proteasome [43]. Similarly, recent studies on chronic myelogenous leukemia
(CML) cells noted that the ubiquitination of β-catenin was increased following niclosamide
treatment [19]. It is very interesting that niclosamide stimulated protein ubiquitination in the
U-87 MG (Fig 2) and U-118 MG (S1 Fig) glioblastoma cell lines, whereas it had no effect on
protein ubiquitination in other human cell lines (S2 Fig). These results are indicative of niclosamide-induced protein ubiquitination being unique to human glioblastoma cells. It is still
unclear whether or not the increase in protein ubiquitination seen in U-87 MG and U-118
MG cells only applies to specific proteins and we want to confirm that induction of protein
ubiquitination results in the formation of large ubiquitin-containing aggregates. In the future,
we plan to more fully characterize the exact underlying mechanisms that allow niclosamide to
induce protein ubiquitination in glioblastoma by utilizing more glioblastoma cell lines.
Another important outcome of this research was the demonstration, for the first time, that
niclosamide induces endoplasmic reticulum (ER) stress in U-87 MG cells. We found that U-87
MG cells exposed to niclosamide showed increased expression of CHOP, a key marker of ER
stress. Moreover, our results showed that niclosamide is able to induce ER stress in a timedependent manner. Thus, the ability of niclosamide to trigger ER stress in U-87 MG cells may
be one mechanism by which niclosamide can trigger cell death of cancer cells and thus function as an effective anticancer agent.
Previous results have shown that niclosamide is able to induce autophagy in various cancer
cells including human neuroblastoma SH-SY5Y cells. Balgi et al. demonstrated that niclosamide induces autophagosome formation and inhibits mTORC1 signaling in MCF-7 breast
cancer cells [26]. Niclosamide also can stimulate both apoptotic and autophagic cell death in
HeLa cells [44]. Gies’s group demonstrated that in SH-SY5Y cells niclosamide prevents
MG132-mediated ubiquitin-containing aggregates by inducing autophagy [32]. Furthermore,
ER stress can induce autophagy in order to reestablish homeostasis [34,36] and we observed
niclosamide triggered ER stress in U-87 MG cells (Fig 3A). Therefore, we examined the effect
of niclosamide on autophagic activation in U-87 MG cells. Consistent with the previous studies on other cell lines, we observed that following niclosamide treatment there was an increase
of autophagy in U-87 MG cells as evidenced by an increase in LC3-II protein and an increase
of MDC staining for autophagosomes in niclosamide treated cells (Fig 3B and 3C). The results
suggest niclosamide elicits the autophagic response and this may occur, at least in part,
through the activation of ER stress. Autophagy has been established as a mechanism that contributes to cell survival, however current investigations have provided strong evidence that,
under certain conditions, autophagy also can promote apoptosis. For example, it has been
reported that treatment with the antimalarial (and anticancer) drug chloroquine is able to trigger autophagy-mediated cell death of glioma cells [45]. Therefore, we hypothesize that the activation of autophagy by niclosamide may partially contribute to the initiation of cell death in
glioma U-87 MG cells. Interestingly, niclosamide-induced activation of autophagy within U87 MG cells corresponded with a rise in protein ubiquitination (Fig 2) whereas in SH-SY5Y
cells the niclosamide-mediated autophagic response led to inhibition of protein ubiquitination.
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Research has shown that there are links between the UPS and autophagy as they have similar
substrates and regulators, such as histone deacetylase 6 (HDAC6) and p62, with ubiquitin
being one key to targeting proteins for degradation by either system [46–47]. Further study is
needed to characterize the underlying mechanism(s) that result in the different responses to
niclosamide by U-87 MG cells and SH-SY5Y cells.
The Wnt signaling pathway plays a pivotal role in human cancer cell growth and carcinogenesis. Multiple publications by various groups have shown that niclosamide is a potent
inhibitor of Wnt/β-catenin signaling. In particular, niclosamide has been reported to inhibit
Wnt/β-catenin signaling in various cancers [23–25,48]. Our data demonstrated that niclosamide is able to down-regulate the expression of Wnt/β-catenin and proteins from their target
genes, cyclin D1 and survivin, in U-87 MG cells as well. The expression of cyclin D1 and survivin significantly decreased in a concentration-dependent manner which correlated with the
results of β-catenin (Fig 4) and phospho-STAT3 expression (Fig 6). The cyclin D1 proto-oncoprotein is a crucial regulator in cell-cycle progression, and aberrant overexpression of cyclin
D1 is linked to tumorigenesis of many different cancer types [49].
Both PI3K/AKT and MAPK/ERK signaling pathways have been reported to play an important role in the tumorigenesis of glioma cells [50–51]. The PI3K/AKT signaling pathway exerts
a critical role in the promotion of cell survival and the inhibition of apoptosis in cancer cells,
especially glioblastoma cells [52–53]. Previous studies have demonstrated that niclosamide
does not impair PI3K/AKT signaling in human breast cancer MCF-7 cells [41], and it has no
effect on this pathway in the human prostate cancer cell line DU145 nor in human glioma cell
line A172 [54]. However, our findings demonstrate that niclosamide is able to inhibit PI3K/
AKT and MAPK/ERK signaling in human glioma U-87 MG cells, which, to the best of our
knowledge, has not been reported in any previous cancer studies. We clearly see a decrease in
AKT and ERK activation following niclosamide treatment (Fig 5). The results indicate that the
inhibition of pro-survival PI3K/AKT and MAPK/ERK signaling pathways may enhance the
effect of niclosamide-induced cell death and thereby niclosamide may be a novel effective anticancer agent against grade IV glioblastoma like the U-87 MG cell line. Again, further study utilizing additional glioblastoma cell lines is required.
Niclosamide has also recently been reported as a potent STAT3 inhibitor that functions as a
tumor suppressor in cancer cells [27]. In agreement with previous studies, we found that both
STAT3 and phospho-STAT3 protein expression in U-87 MG cells was dramatically reduced
upon exposure to niclosamide (Fig 6). MAPK/ERK signaling is one of the many pathways that
is capable of regulating STAT3 via phosphorylation [55]. Therefore, suppression of ERK by
niclosamide may partially contribute to inhibition of STAT3. STAT3 plays an important role
in anti-apoptotic signaling within various cancer cells [9,56]. High levels of STAT3 activity
have been found to predict intrinsic chemotherapy resistance and STAT3 inhibition allows
glioblastoma cells to overcome temozolomide resistance which is a significant finding given
that temozolomide is a first-line treatment for glioblastoma [2,57]. Furthermore, STAT3 is
required for proliferation and maintenance of multipotency in glioblastoma stem cells [56].
Our results imply that niclosamide-mediated inhibition of STAT3 may contribute to the overall efficacy of niclosamide as a tumor suppressor to repress U-87 MG cell proliferation and
promote cell death.
The present study demonstrated that niclosamide potently induced protein ubiquitination,
endoplasmic reticulum stress and autophagy in human glioblastoma cells and considerably
disrupted multiple signal transduction pathways that have been reported to be associated with
glioblastoma development (Fig 7). Wnt/β-catenin, MAPK/ERK, PI3K/AKT and STAT3 signaling are highly activated in glioma, so it is conceivable that simultaneous pharmacological inhibition of all these signaling pathways might be the most effective therapeutic strategy for the
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Fig 7. Schematic representation of niclosamide-mediated molecular mechanisms within human
glioblastoma U-87 MG cell line. Niclosamide simultaneously inhibited multiple pro-survival signal
transduction pathways and it activated other major cellular responses that inhibit cell proliferation and survival
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and facilitate cell death. Green lines represent activation/promotion of molecular pathways and red lines
represent inhibition of cell signaling.
https://doi.org/10.1371/journal.pone.0184324.g007

prevention and treatment of glioblastoma. As our findings show, niclosamide appears to
inhibit all these pathways within U-87 MG cells, resulting in decreased cell proliferation and
increased cell death. Therefore, it would be of great interest to identify the mechanism(s)-ofaction against these targets. Although its exact mode of action as an anthelmintic drug has
remained unclear, niclosamide is believed to owe its anti-parasitic activity to its ability to
uncouple oxidative phosphorylation (OP), block glucose uptake, and inhibit respiration in
anaerobic ATP production [58–59]. Structurally, niclosamide is very similar to dinitrophenol
(DNP), an antiseptic and a pesticide that also was used as a diet aide in the 1930s, enabling it to
uncouple OP in the mitochondria during electron transport from NADH to flavoprotein [60].
In fact, niclosamide has been reported to target mitochondria in cancer cells to induce cell
cycle arrest, growth inhibition and apoptosis [15]. It is possible that the mitochondria within
glioblastoma cells are one of the targets of niclosamide, given that niclosamide has demonstrated a proton carrier mode-of-action independent of any protein target [61]. Niclosamide
might cause an inward flux of protons through the mitochondrial membrane in glioblastoma
cells and thereby dissipate proton gradients across the membrane to impair mitochondrial
functions, which, in turn, would interfere with multiple pro-survival signaling pathways. A
similar explanation might also apply to the cell membrane: niclosamide might target the cytoplasmic membrane of U-87 MG cells and induce intracellular acidification to disrupt pH
homeostasis [41]. In fact, this hypothesis is consistent with some recent observations that
intracellular acidification was able to induce protein ubiquitination in yeast [62]. Furthermore,
it also is possible that niclosamide may target specific protein receptors on the surface of the
cell, receptors that may be required for triggering the major signaling pathways.

Conclusion
The present investigation demonstrates the tumor suppressive properties of niclosamide in
human glioma U-87 MG cells. Niclosamide treatment simultaneously inhibited multiple key
cell signaling pathways that are involved in cell proliferation and survival and it resulted in the
initiation of ER stress, autophagy, and apoptosis. Even more interestingly, niclosamide acted
like a proteasome inhibitor and markedly induced expression of abundant ubiquitinated proteins in U-87 MG cells, which mostly likely contributed to its effectiveness in suppressing cell
survival and promoting cell death. It is rare to find a drug, especially one that has been established as safe for human use, which can target so many intracellular pathways involved in carcinogenesis. Overall, these results suggest that niclosamide may be a novel potential
therapeutic candidate for the treatment of glioblastoma.

Supporting information
S1 Fig. Effect of niclosamide on protein ubiquitination in human U-118 malignant glioblastoma cell line. The human U-118 MG cell line was purchased from ATCC (Manassas,
VA) and were cultured in DMEM medium containing 10% FBS at 37˚C, 5% CO2. Cell lines
were treated with the indicated concentrations of niclosamide for 24 h and then total cell
lysates were collected. Protein was resolved by SDS-PAGE and immunoblotted with antibody
specific to ubiquitin. β-Actin was utilized as a loading control.
(TIF)
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S2 Fig. Effect of niclosamide on protein ubiquitination in human cell lines. Cell lines were
purchased from ATCC. BJ skin fibroblast cells (A) were cultured in EMEM containing 10%
FBS; U-2 OS cells (B) were cultured in McCoy’s 5A medium containing 10% FBS; and MCF-7
(C) and MDA-MB-231 (D) cells were cultured in DMEM medium containing 10% FBS at
37˚C, 5% CO2. Cell lines were treated with the indicated concentrations of niclosamide for 24
h and then total cell lysates were collected. Protein was resolved by SDS-PAGE and immunoblotted with antibody specific to ubiquitin. β-Actin was utilized as a loading control.
(TIF)
S3 Fig. Effect of niclosamide on proteasome activity. U-87 MG cells were treated with the
indicated concentrations of niclosamide for 24 h. 20S proteasome activity was quantified by a
colorimetric assay (Cayman Chemical Company, Ann Arbor, MI) read at 480 nm and normalized by cell number. Data represent the mean ± S.E.M of at least three independent experiments.
(TIF)
S4 Fig. Data set for statistical analysis of cell viability following niclosamide treatment (Fig
1).
(XLSX)
S5 Fig. Data set for statistical analysis of western blot densitometry (Fig 2).
(XLSX)
S6 Fig. Data set for statistical analysis of proteasome activity following niclosamide treatment (S3 Fig).
(XLSX)
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